Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Vorinostat in Advanced Metastatic Soft Tissue Sarcomas
2008-008513-19Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jun 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in soft tissue sarcoma (STS) and extraskeletal myxoid chondrosarcoma (EMC), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-free survival. Started Jun 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
soft tissue sarcoma (STS)extraskeletal myxoid chondrosarcoma (EMC)
Beyond the preview
Go deeper on 2008-008513-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008513-19.